47 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
27020306	18	Discovery of KDM5A inhibitors: Homology modeling, virtual screening and structure-activity relationship analysis.	Sichuan University
26710088	248	Recent Progress in Histone Demethylase Inhibitors.	University of Oxford
26700437	32	Identification of SNAIL1 Peptide-Based Irreversible Lysine-Specific Demethylase 1-Selective Inactivators.	Kyoto Prefectural University of Medicine
26699912	108	Docking and Linking of Fragments To Discover Jumonji Histone Demethylase Inhibitors.	University of Oxford
26101571	45	Identification of Jumonji AT-Rich Interactive Domain 1A Inhibitors and Their Effect on Cancer Cells.	Kyoto Prefectural University of Medicine
24040942	632	Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3.	University of North Carolina At Chapel Hill
23964788	56	Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity.	Kyoto Prefectural University of Medicine
27499454	22	Design and evaluation of 1,7-naphthyridones as novel KDM5 inhibitors.	Genentech
27476424	56	Identification of potent, selective KDM5 inhibitors.	Constellation Pharmaceuticals
27406798	92	Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies.	Genentech
30745098	24	Identification of novel lysine demethylase 5-selective inhibitors by inhibitor-based fragment merging strategy.	Kyoto Prefectural University of Medicine
30928196	5	Identification of ortho-hydroxy anilide as a novel scaffold for lysine demethylase 5 inhibitors.	Kyoto Prefectural University of Medicine
26682034	229	Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor.	University of Oxford
24466405	213	The structure-activity relationships of L3MBTL3 inhibitors: flexibility of the dimer interface.	University of North Carolina
30392349	34	Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A.	The University of Texas M.D. Anderson Cancer Center
29627262	109	Structure-based design and discovery of potent and selective KDM5 inhibitors.	Celgene
28478342	46	Methyllysine binding domains: Structural insight and small molecule probe development.	University of Connecticut
29764755	85	Investigations on small molecule inhibitors targeting the histone H3K4 tri-methyllysine binding PHD-finger of JmjC histone demethylases.	University of Oxford
28512031	65	From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors.	Genentech
29537847	30	Insights into the Action of Inhibitor Enantiomers against Histone Lysine Demethylase 5A.	The University of Texas M.D. Anderson Cancer Center
28539219	7	Discovery of pyrazolo[1,5-a]pyrimidine-3-carbonitrile derivatives as a new class of histone lysine demethylase 4D (KDM4D) inhibitors.	Sichuan University
1464308	17	The mouse 5HT5 receptor reveals a remarkable heterogeneity within the 5HT1D receptor family.	Cnrs
	12	Calorimetric Studies on the Complexation of Several Ferrocene Derivatives by .alpha.- and .beta.-Cyclodextrin. Effects of Urea on the Thermodynamic Parameters	University of Miami
19168353	25	Discovery and SAR of para-alkylthiophenoxyacetic acids as potent and selective PPARdelta agonists.	Johnson & Johnson Pharmaceutical
19237286	30	Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding.	Gsk
19260677	11	Structure-activity relationships of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents.	Toronto General Research Institute
18054488	24	Novel thiol-based TACE inhibitors. Part 2: Rational design, synthesis, and SAR of thiol-containing aryl sulfones.	Vertex Pharmaceuticals
18640037	48	Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-ray crystallographic studies.	Universita Degli Studi Di Firenze
18729351	21	Potent cationic inhibitors of West Nile virus NS2B/NS3 protease with serum stability, cell permeability and antiviral activity.	University of Queensland
15454208	48	SAR and factor IXa crystal structure of a dual inhibitor of factors IXa and Xa.	Bristol-Myers Squibb
14998327	12	Structure-based optimization of novel azepane derivatives as PKB inhibitors.	Roche Diagnostics
28841282	2	Synthetic Lethality Triggered by Combining Olaparib with BRCA2-Rad51 Disruptors.	Istituto Italiano Di Tecnologia